Details of Disease

General Information of Disease (ID: DIS8MM3L)

Disease Name	Gram-negative bacterial infection
Synonyms	bacterial infections, gramme negative; gramme negative bacterial infections; bacterial infections, gram-negative; infection, gram-negative bacterial; gram-negative bacterial infection; bacterial infections, gram negative; bacterial infection, gram-negative; infections, gramme negative bacterial; gram negative bacterial infections; infections, gram negative bacterial; infections, gram-negative bacterial
Disease Class	1F41-1G40: Gram-negative bacterial infection
Definition	Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.\|Editor note: this does not correspond to a taxonomic grouping, so classification is manual for now
Disease Hierarchy	DIS5QJ9S: Bacterial infection DIS8MM3L: Gram-negative bacterial infection
ICD Code	ICD-11 ICD-11: 1B74-1G40 Expand ICD-9 1.00E+183
Disease Identifiers	MONDO ID MONDO_0021678 MESH ID D016905 UMLS CUI C0085423 MedGen ID 88406 SNOMED CT ID 371583007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Apramycin	DMU8QD2	Phase 1	Small molecular drug	[1]
MRX-8	DMDYSMJ	Phase 1	NA	[2]
QPX7831	DMD2P1X	Phase 1	NA	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RC-01	DM4FNWO	Terminated	NA	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AOAH	TT2EJXQ	Strong	Biomarker	[5]
CASP4	TT6KIOT	Strong	Biomarker	[6]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
RNASE3	OTVE2XD1	moderate	Therapeutic	[7]
GSDMD	OTH39BKI	Strong	Biomarker	[6]
PHLPP1	OTIFXW8D	Strong	Altered Expression	[8]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04105205) First-In-Human Study of Apramycin. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04649541) An Adaptive, Randomized, Double Blind, Placebo Controlled Three Part Study of the Safety, Tolerability, and Pharmacokinetics of MRX-8 Administered Intravenously to Healthy Volunteers in Single Ascending and Multiple Ascending Dose Cohorts. U.S.National Institutes of Health.
3	ClinicalTrials.gov (NCT04578873) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Oral QPX7831 in Healthy Adult Subjects. U.S.National Institutes of Health.
4	The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020 May;18(5):275-285.
5	Acyloxyacyl hydrolase promotes the resolution of lipopolysaccharide-induced acute lung injury.PLoS Pathog. 2017 Jun 16;13(6):e1006436. doi: 10.1371/journal.ppat.1006436. eCollection 2017 Jun.
6	A genome-wide screen identifies IRF2 as a key regulator of caspase-4 in human cells.EMBO Rep. 2019 Sep;20(9):e48235. doi: 10.15252/embr.201948235. Epub 2019 Jul 29.
7	Refining the eosinophil cationic protein antibacterial pharmacophore by rational structure minimization.J Med Chem. 2011 Jul 28;54(14):5237-44. doi: 10.1021/jm200701g. Epub 2011 Jul 1.
8	Leptin signaling impairs macrophage defenses against Salmonella Typhimurium.Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16551-16560. doi: 10.1073/pnas.1904885116. Epub 2019 Jul 26.